ESCITALOPRAM OXALATE Drug Patent Profile
✉ Email this page to a colleague
When do Escitalopram Oxalate patents expire, and what generic alternatives are available?
Escitalopram Oxalate is a drug marketed by Mylan Pharms Inc, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Lannett Co Inc, Macleods Pharms Ltd, Taro, Accord Hlthcare, Cadila, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Generics, Lupin Ltd, Mylan, Pharm Assoc, Prinston Inc, Teva Pharms Usa, and Torrent Pharms Ltd. and is included in twenty-three NDAs.
The generic ingredient in ESCITALOPRAM OXALATE is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Escitalopram Oxalate
A generic version of ESCITALOPRAM OXALATE was approved as escitalopram oxalate by AMNEAL PHARMS on March 14th, 2012.
Summary for ESCITALOPRAM OXALATE
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 41 |
Raw Ingredient (Bulk) Api Vendors: | 81 |
Clinical Trials: | 20 |
Patent Applications: | 622 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ESCITALOPRAM OXALATE |
Drug Sales Revenues: | Drug sales revenues for ESCITALOPRAM OXALATE |
What excipients (inactive ingredients) are in ESCITALOPRAM OXALATE? | ESCITALOPRAM OXALATE excipients list |
DailyMed Link: | ESCITALOPRAM OXALATE at DailyMed |


See drug prices for ESCITALOPRAM OXALATE

Recent Clinical Trials for ESCITALOPRAM OXALATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NYU Langone Health | Phase 4 |
National Institute on Aging (NIA) | Phase 4 |
Xijing Hospital | N/A |
Pharmacology for ESCITALOPRAM OXALATE
Drug Class | Serotonin Reuptake Inhibitor |
Mechanism of Action | Serotonin Uptake Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ESCITALOPRAM OXALATE
Paragraph IV (Patent) Challenges for ESCITALOPRAM OXALATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LEXAPRO | Capsules | escitalopram oxalate | 5 mg | 021323 | 1 | 2005-08-17 |
LEXAPRO | Capsules | escitalopram oxalate | 10 mg and 20 mg | 021323 | 1 | 2005-03-30 |
US Patents and Regulatory Information for ESCITALOPRAM OXALATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 077550-001 | May 14, 2015 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Jubilant Generics | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 202280-001 | Sep 12, 2012 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
Prinston Inc | ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 078032-003 | Aug 28, 2015 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |